Related Experiment Video
Updated: Jul 8, 2026

Methyl-binding DNA capture Sequencing for Patient Tissues
Published on: October 31, 2016
Determination of global DNA methylation level by methylation-sensitive comet assay in patients with urinary bladder
Ozer Kocak1, Selin Kankaya2, Goktug Kalender3
1Department of Medical Biochemistry, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul 34098, Turkey.
Abstract:
DNA methylation is an important mechanism in the regulation of gene expression and maintenance of genomic integrity. Aberrant DNA methylation is an early event in carcinogenesis. DNA methyltransferase inhibitors are used to restore aberrant DNA methylation and inhibit tumor growth. Evaluation of DNA methylation level is important for an effective anti-cancer therapy. In the present study, the determination of global DNA methylation levels in patients with urinary bladder cancer was proposed. The methylation-sensitive comet assay determined the global DNA methylation level at the level of single cells. McrBC enzyme, a methylation-sensitive restriction endonuclease, was used for enzymatic digestion to generate additional breaks at methylated sites. % DNA methylation level was significantly higher in patients with bladder cancer compared to the control group. The clinical performance of % DNA methylation analysis by methylation-sensitive comet assay was evaluated by ROC curve. Using the cutoff value of 6.5% DNA methylation, 92% sensitivity, and 42% specificity were obtained. In conclusion, global DNA methylation measured by methylation-sensitive comet assay may be a promising noninvasive biomarker that reduces interventional tests required in the diagnosis and follow-up of urinary bladder cancer.
Insights
Global DNA methylation levels are significantly higher in bladder cancer patients. Methylation-sensitive comet assay shows potential as a noninvasive biomarker for early cancer detection and monitoring.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- DNA methylation regulates gene expression and genomic stability.
- Aberrant DNA methylation is linked to early carcinogenesis.
- Evaluating DNA methylation is crucial for effective anti-cancer therapy.
Purpose of the Study:
- To determine global DNA methylation levels in urinary bladder cancer patients.
- To assess the utility of the methylation-sensitive comet assay for this purpose.
Main Methods:
- Global DNA methylation levels were measured using the methylation-sensitive comet assay.
- McrBC enzyme was employed for enzymatic digestion at methylated sites.
- Receiver Operating Characteristic (ROC) curve analysis evaluated clinical performance.
Main Results:
- Global DNA methylation levels were significantly elevated in bladder cancer patients compared to controls.
- The methylation-sensitive comet assay achieved 92% sensitivity and 42% specificity with a 6.5% DNA methylation cutoff.
Conclusions:
- Global DNA methylation measured by methylation-sensitive comet assay is a potential noninvasive biomarker.
- This assay may reduce the need for invasive diagnostic and follow-up procedures in urinary bladder cancer.
Related Concept Videos
Serum Laboratory Studies, Stool Test, Breath Test
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
Urine Studies II: Urine Culture and Sensitivity Test

